KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Edwards Lifesciences (EW) EBT (2016 - 2025)

Historic EBT for Edwards Lifesciences (EW) over the last 17 years, with Q3 2025 value amounting to $348.4 million.

  • Edwards Lifesciences' EBT fell 1350.55% to $348.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 310.78%. This contributed to the annual value of $1.5 billion for FY2024, which is 1280.24% up from last year.
  • Latest data reveals that Edwards Lifesciences reported EBT of $348.4 million as of Q3 2025, which was down 1350.55% from $400.2 million recorded in Q2 2025.
  • Over the past 5 years, Edwards Lifesciences' EBT peaked at $545.5 million during Q2 2021, and registered a low of $211.4 million during Q4 2022.
  • Moreover, its 5-year median value for EBT was $390.1 million (2024), whereas its average is $388.5 million.
  • Per our database at Business Quant, Edwards Lifesciences' EBT soared by 42431.63% in 2021 and then plummeted by 4382.14% in 2022.
  • Edwards Lifesciences' EBT (Quarter) stood at $376.3 million in 2021, then crashed by 43.82% to $211.4 million in 2022, then surged by 73.7% to $367.2 million in 2023, then increased by 6.24% to $390.1 million in 2024, then dropped by 10.69% to $348.4 million in 2025.
  • Its EBT stands at $348.4 million for Q3 2025, versus $400.2 million for Q2 2025 and $433.9 million for Q1 2025.